

# *Derbyshire Joint Area Prescribing Committee Annual Report*

## *April 2016 - March 2017*

[www.derbyshiremedicinesmanagement.nhs.uk](http://www.derbyshiremedicinesmanagement.nhs.uk)

Promoting Evidence-based, Cost-effective, Safe Prescribing

**June 2017**

*Authors*

Sadaf Qureshi – NICE Audit Pharmacist

Kate Stanley – Senior Administration Officer

## **Forward**

Welcome to the 2016/17 annual report of Derbyshire Joint Area Prescribing Committee (JAPC), and thank you for reading it.

JAPC continues to function at a high level to promote safe and effective use of medicines and medical devices across Derby and Derbyshire. This is due to the ongoing commitment of all members of the committee, including all our large NHS providers and all CCGs in our area. We continue to rely on the professional approach and tenacity of the Clinical Effectiveness Team, led by Slak Dhadli, to serve JAPC, maintain our processes and ensure high quality clinical input to our work and guidance. This is delivered by means of the long-standing Guideline Group that sits beneath JAPC to develop the guidelines and maintain our formulary.

This year we instigated a second subgroup under JAPC, named the JAPC Working Group. This is ably chaired by Dr Tim Parkin from Hardwick CCG, and aims to work collaboratively across our STP footprint to identify ways of reducing medicines waste, increasing self-care, and consider other areas where the spend on prescriptions could be reduced. The membership of this group is wider than JAPC, and includes NHS England, Derbyshire Local Medical Committee and the Derbyshire Local Pharmaceutical Committee. The outputs of this group are put forward for JAPC for decision.

The Regional Medicines Optimisation Committees (RMOCs) are shortly to be established, and will clearly have bearing on JAPC's work. We hope to have Derbyshire representation on the RMOC to ensure we are well informed as it develops.

Finally, I'd like to thank all those across the system who have contributed to JAPC's work in the past year. Your help is much appreciated.

Dr Andrew Mott  
Chair, Derbyshire Joint Area Prescribing Committee

### **Key achievements in 2016-17**

1. *All 12 meetings held during 2016-17 were quorate*
2. *Agreement of Derbyshire Joint Area Prescribing Committee prescribing specification for 2017-19*
3. *150 drugs received a traffic light classification*
  - a. *47 drugs were classified as part of the monthly horizon scan*
  - b. *23 were new drug requests*
  - c. *52 drugs were classified based on NICE guidance*
  - d. *14 drugs were classified in-light of updated local guidance*
  - e. *14 drugs were reclassified*
4. *39 clinical guidelines were approved for use across Derbyshire*
5. *14 shared care agreements were approved for use across Derbyshire*
6. *39 PGDs were ratified of which 20 were local PGDs (for use in Derbyshire only).*
7. *26 MHRA drug safety alerts relevant to primary care were noted, and formulary/guidance updated to reflect the alert.*
8. *2 direct healthcare professional Communications were included into the relevant guidance and BNF formulary chapters.*
9. *One patient safety alert noted.*

## **Introduction**

### **The purpose of the committee**

JAPC is an important strategic network with the responsibility for promoting cost-effective use of medicines and medical devices and supporting functional integration in healthcare delivery. Each of its stakeholder organisations/bodies gains benefit from working in a co-ordinated manner across Derby and Derbyshire.

### **Aims of JAPC**

JAPC is a strategic committee with responsibility for promoting appropriate, safe, rational, and cost-effective use of medicines and medical devices in Derbyshire. JAPC has delegated decision-making responsibility for pharmaceutical governance on behalf of Integrated Governance for the four Clinical Commissioning Groups (CCG) wholly within Derbyshire. Decisions represent standards of good practice, and are normally expected to be implemented. JAPC has no delegated responsibility for resource allocation.

JAPC's key aims are:

1	To ensure high standards of pharmaceutical governance
2	To maintain an area drug formulary
3	To maintain the traffic light classification for prescribing responsibility
4	To develop local clinical guidelines and shared care guidelines for amber drugs
5	To advise on implementation of NICE guidance/guidelines that concern drug use
6	To advise on the commissioning and provision of new drugs and new indications
7	To review key clinical trials and advise on their implications

### **JAPC Prescribing Specification.**

The prescribing specification is part of the healthcare services contract CCG commissioners hold with all NHS provider organisations. This document outlines the role and responsibilities of our provider trusts in ensuring a transparent and collaborative approach to the safe and effective management of medicines, seamless care of patients between NHS organisations and ensuring high quality prescribing. The document is updated annually for changes in process and best practice and taken to JAPC (with representatives from both commissioner and provider organisations across Derbyshire) to ensure that its requirements are both fair and reasonable. Once agreed by JAPC, the specification can then be included as part of the contract prescribing requirements from providers for the following contract year. It is also used for prescribing contractual arrangements with provider organisations who are not key stakeholders of JAPC.


### **Membership**

The JAPC serves the following participating organisations:

- NHS Southern Derbyshire CCG
- NHS North Derbyshire CCG
- NHS Hardwick CCG
- NHS Erewash CCG
- Derbyshire Community Health Services NHS Foundation Trust (DCHSFT)
- Chesterfield Royal Hospital NHS Foundation Trust (CRHFT)
- Derby Teaching Hospitals NHS Foundation Trust (DTHFT)
- Derbyshire Healthcare NHS Foundation Trust (DHcFT)
- Public Health, Derby City and Derbyshire County Councils

Membership of the committee comprises a wide variety of professional, clinical, commissioning, managerial, and organisational backgrounds.

# Derbyshire Joint Area Prescribing Committee Stakeholder map



## Attendance

Name & title		Attendance
<b>Southern Derbyshire CCG</b>		
Dr A Mott ( <i>Chair</i> )	GP	11
Mr S Dhadli ( <i>Secretary</i> )	Specialist Commissioning Pharmacist	10
Mr S Hulme	Director of Medicines Management (& Erewash CCG)	10
Mrs Sadaf Qureshi	NICE audit Pharmacist	11
Dr M Watkins	GP	11
Mrs L Hunter	Assistant Chief Finance Officer	10
Ms N Smith ( <i>Deputy for L Hunter</i> )	Finance Officer	1
Ms Y Soetan ( <i>Deputy for S Hulme</i> )	Lead Pharmacist	2
<b>North Derbyshire CCG</b>		
Dr C Emslie ( <i>Deputy Chair</i> )	GP	8
Dr T Narula* ( <i>from April 2016</i> )	GP	9
Mrs K Needham	Head of Medicines Management (& Hardwick CCG)	9
Ms J Town	Head of Finance Commissioning	7
Mr Jon Vinson ( <i>Deputy for K Needham</i> )	Lead Medicines Management Pharmacist	2
Ms M North ( <i>Deputy for K Needham</i> )	Pharmacist, North Medicines Management (& Hardwick CCG)	1
Mr R Coates ( <i>Deputy for J Town</i> )	Management Accountant	4
<b>Hardwick CCG</b>		
Dr T Parkin	GP	11
<b>Erewash CCG</b>		
Dr M Henn	GP	10
Mrs H Murch* ( <i>Deputy for Dr Henn</i> )	Lead Pharmacist	1
<b>Derby Teaching Hospitals NHS Foundation Trust</b>		
Dr W Goddard	Drugs & Therapeutics Committee Chair	10
Mr C Newman	Chief Pharmacist	10
<b>Chesterfield Royal Hospital</b>		
Mr M Shepherd	Head of Medicines Management	10
Ms C Duffin ( <i>Deputy for M Shepherd</i> )	Pharmacist	2
<b>Derbyshire Community Health Services</b>		
Mr M Steward ( <i>until June 2016</i> )	Chief Pharmacist	3
Ms J Shaw ( <i>Deputy for M Steward</i> )	Pharmacist	6
Ms A Braithwaite ( <i>From Sept 2016</i> )	Chief Pharmacist	3
<b>Derbyshire Healthcare Foundation Trust</b>		
Dr S Taylor	Drugs & Therapeutics Committee Chair	7
Ms S Bassi	Chief Pharmacist	3
Mrs B Thompson	Pharmacist	2
<b>Derby City Council</b>		
Dr R Dewis	Consultant In Public Health Medicine	5

## Drugs classified under the Traffic Light System (April 2016 – March 2017)

Black (27)	Brown (18)	Red (86)	Amber (2)	Green (17)
Not recommended or commissioned	Not recommended for use except in exceptional circumstances	Hospital/ specialist only	Shared care	Suitable for primary care
Alimemazine Dec  New drug	Brivaracetam (after specialist/consultant initiation and stabilisation for three months in patients that have responded to levetiracetam but unable to tolerate the adverse effects) Feb	Abiraterone (as per NICE TA 387) May	Degarelix (as per NICE TA 404) no change Sept	Ceftriaxone 1g and 2g, Ertapenem 1g, Teicoplanin 800mg, Tazocin 4.5g and meropenem 1g (only as part of the OPAT service between DCHSFT and CRHFT) Feb
Azacitinide (as per NICE TA 399) Aug	Budesonide MR (specialist initiation) Jan	Adalimumab (as per NICE TA 392) Jul	Lisdexamfetamine (2nd line option for the treatment of ADHD within the shared care guideline) Oct	Ciprofloxacin 0.3% / dexamethasone 0.1% ear drops (Cilodex®) (for use in patients with acute otitis media with tympanostomy tubes or tympanic perforation in adults and children over 6 months of age) Dec
Bazedoxifene + conjugated oestrogens (Duavive®) Jan	Buprenorphine patches (use most cost effective brand) Dec	Aflibercept (as per NICE TA 409) Oct		Desunin® (as alternative formulary choice for maintenance) May
Cobimetinib in combination with vemurafenib (as per NICE TA 414 NHS England) Nov	Canagliflozin and dapagliflozin (Alternatives to empagliflozin if intolerant or restriction by licensing). Jul	Alipogene tiparovec (Glybera®) (NHS England) Sept		Donepezil (1st line after specialist initiation and stabilisation for three months) Mar
Dapagliflozin + Saxagliptin (Qtern®) Mar	Ciclosporin (Ikervis) eye drops (specialist initiation) Mar	Alirocumab (re-classified from BLACK) Apr		Empagliflozin (Preferred 1st line SGLT2 inhibitor) Jul
Doxazosin MR Feb	Dapagliflozin (as per NICE TA 418 and 288) Dec	Alpha-1 antitrypsin (Respreeza®) Mar		Fultium D3® (preferred formulary choice for treatment of Vitamin D deficiency. Cost effective choice for treatment and maintenance) May
EyeBag Aug	Dequalinium vaginal tablets (Fluomizin®) (2nd line to metronidazole) Dec	Apremilast (as per NICE TA 419) Dec		Galantamine (2nd line after specialist initiation and stabilisation for three months) Mar
Gemcitabine (as per NICE TA 389) May	Flumetasone/Clioquinol 0.02%/1% w/v ear drops solution Dec	Apremilast (as per NICE TA433) Mar		Influenza vaccines (as per National Vaccination Programme) Mar
Ixekizumab Aug	Glycopyrronium oral medication (Sianalar®) (2nd line specialist/consultant initiation for children after trial or consideration of hyoscine oral and/or patches) Mar	Arsenic (Trisenox®) (NHS England) Jan		Invita D3® (cost effective option in patients with swallowing difficulties for treatment and maintenance) May
Lidocaine + prilocaine (Fortacin®) Jan	Hydrocortisone and gentamicin ear drops Dec	Asparaginase recombinant (Spectrila®) (NHS England) Oct		Low Molecular Weight Heparin (Enoxaparin, Tinzaparin) (after specialist initiation) Feb
Liraglutide (Saxenda®) (for weight management) Mar	Hydromorphone (after specialist/consultant initiation after other strong opioids had been tried) Feb	Ataluren (as per NICE HST3) Aug		Medroxyprogesterone acetate (Sayana Press®) (after appropriate patient training) Mar
Lumacaftor/Ivacaftor (as per NICE TA 398) Aug	Ibandonate 50mg (for off-licence use in post-menopausal women in breast cancer with Sheffield Teaching Hospitals Foundation Trust only as per guidance to improve breast cancer survival. Note dual traffic light classification - RED for all other use) Aug	Belimumab (as per NICE TA 397) Jul		Memantine hydrochloride (2nd line after specialist initiation and stabilisation for three months) Mar

Lurasidone (re-classified from RED) Apr	Liraglutide and exenatide (daily dosing) (Alternatives to lixisenatide if intolerant or restriction by licensing). Jul	Benzbromarone May		Metolozone (after specialist recommendation) May
Maculeh Light	Nortriptyline (2nd line to amitriptyline) Dec	Blinatumomab Aug		Rivastigmine (2nd line after specialist initiation and stabilisation for three months) Mar
Necitumumab (as per NICE TA 411 NHS England) Oct	Pioglitazone Aug	Bosutinib (NHS England as per NICE TA 401) Sept		Spirolactone May
Nefopam Nov	Repaglinide (Limited for use in patients with early diabetes or in patients with erratic lifestyles) Jul	Brentuximab vedotin (Adcetris®) (NHS England) Sept		Tamoxifen (specialist initiation to prevent bicalutamide induced gynaecomastia) Jul
Olodaterol+tiotropium (Spiolto Respimat) Jul	Tadalafil daily formulation (2nd line to sildenafil (given up to daily) Jan	Brivaracetam Apr		Ulipristal Acetate (Esmya®) after specialist/consultation 1st course as per local guideline for treatment of uterine fibroids Sept
Opicapone (Ongentys®) Dec	Ticagrelor 60mg dose (specialist initiation as per NICE TA 420) Jan	Cabazantinib (Cabometyx®) Dec		
Ramucirumab (as per NICE TA 403) Sept		Cabazitaxel (as per NICE TA 391) Jun		
Rubefacients (All rubefacients to be classified as BLACK) Mar		Cabazitaxel (as per NICE TA 391) no change Sept		
Saline nasal sprays (e.g. Sterimar®, Aqua Maris®) May		Ceritinib (as per NICE TA 395) Jul		
Shower Gels/Bath Emollients Sept		Certolizumab pegol (as per NICE TA 415) Nov		
Tiotropium + olodaterol inhaler (Spiolto Respimat) for COPD Jun		Clevipidine May		
Ticagrelor (60mg dose) (for MI) May		Crizotinib (as per NICE TA 406 NHS England) Oct		
Topotecan (as per NICE TA 389) May		Crizotinib (as per NICE TA 406 NHS England) Jan		
Trabectedin (as per NICE TA 389) May		Dalbavancin (Xydalba®) Mar		
Trimipramine Jan		Daratumumab Aug		
		Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (as per NICE TA 425 NHS England) Jan		
		Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (as per NICE TA 426 NHS England) Jan		
		Decitabine (Dacogen®) (NHS England) Sept		
		Deferasirox (Exjade®) (NHS England) Jan		
		Doxorubicin hydrochloride (PLDH) (as per NICE TA 389) May		
		Eftrenonacog alfa (Alprolix®) (NHS England) Sept		
		Elbasvir/grazoprevir (as per TA 413 NHS England) Nov		
		Elotuzumab Aug		

		Emticitabine/Tenofovir Aug		
		Eribulin (as per NICE TA 423 NHS England) Jan		
		Etanercept (Benepali®) Biosimilar Apr		
		Everolimus with exemestane (as per NICE TA 421 NHS England) Jan		
		Everolimus (as per NICE TA432) Mar		
		Evolocumab (re-classified from BLACK) Apr		
		Factor IX, recombinant (Rixubis®) Dec		
		Ferric Maltol Aug		
		Grazoprevir + elbasvir (Zepatier®) (NHS England already has a RED traffic light classification as TA413) Feb		
		Guanfacine Jun		
		Human Coagulation Factor X Aug		
		Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (NHS England as per NICE TA 429) Feb		
		Levofloxacin nebuliser solution Aug		
		Mepolizumab for treating severe refractory eosinophilic asthma (NHS England as per NICE TA 431) Feb		
		Migalastat Mar		
		Necitumumab Jul		
		Nitisinone (Orfadin) Apr		
		Nivolumab/ipilimumab (as per NICE TA 400) Aug		
		Nivolumab (as per NICE TA 417) Dec		
		Olaratumab (Lartruvo®) (NHS England) Jan		
		Oscillating PEP Devices (e.g Flutter®/Acapella®) for specialist physiotherapist use only Sept		
		Osimertimib (NHS England) May		
		Osimertinib (as per NICE TA 416 NHS England) Nov		
		Paclitaxel (as per NICE TA 389) May		
		Palbociclib (Ibrance®) (NHS England) Feb		
		Pegaspargaseas (NICE TA 408 NHS England) Oct		



		Pegaspargase (Oncaspar®) (NHS England already has a RED traffic light classification as per TA408) Feb		
		Pembrolizumab for treating PDL1-positive non-small cell lung cancer after chemotherapy (NHS England as per NICE TA 428) Feb		
		Pemetrexed (NHS England as per NICE TA 402) Sept		
		Pertuzumab (as per NICE TA 424 NHS England) Jan		
		Pitolisant (Wakix®) (NHS England) Nov		
		Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (NHS England as per NICE TA 427) Feb		
		Radium-223 dichloride (as per NICE TA 412 NHS England) Oct		
		Reslizumab (Cinqaero®) (NHS England) Dec		
		Ruxolitinib (re-classified from BLACK) as NICETA386 Apr		
		Sacubitril valsartan (as per NICE TA 388) May		
		Sayana Press Aug		
		Secukinumab (as per NICE TA 407) Oct		
		Selexipag (Uptravi®) (NHS England) Oct		
		Sofosbuvir + velpatasvir (Epclusa®) (NHS England) Sept		
		Sofosbuvir– velpatasvir for treating chronic hepatitis C (NHS England as per NICE TA 430) Feb		
		Susoctocog alfa (Obizur®) (NHS England) Oct		
		Talimogene laherparepvec (NHS England) May		
		Talimogene laherparepvec (as per NICE TA 410) Oct		
		Teduglutide (Revestive®) (NHS England) Sept		
		Tobramycin (Xydalba®) Mar		
		Trametinib (as per NICE TA 396) Jul		
		Trifluridine–tipiracil (NHS England as per NICE TA 405) Sept		
		Turoctocog alfa (NoveEight®) (NHS England) Nov		
		Venetoclax (Venclexta®) (NHS England) Feb		
		Zoledronate Mar		

### **Clinical guidelines ratified**

- Managing Behaviour Problems in Patients with Dementia (BPSD) Policy (Apr-16)
- Domperidone - Off-licence use Metoclopramide use in gastro-paresis and other gastric outlet physiological impairment (May-16)
- Management of Heart Failure with Reduced Ejection Fraction (May-16)
- Midodrine prescribing for orthostatic hypotension (May-16)
- North Derbyshire Algorithm for Antiplatelet Therapy in Primary PCI – STEMI (May-16)
- Management of Sub-therapeutic INR (May-16)
- Fosfomycin for multi-resistant UTIs (May-16)
- Prevention, Diagnosis and Management of Vitamin D Deficiency in Primary Care (May-16)
- Buccal Midazolam Information Sheet (Jun-16)
- Oral Nutrition Support (ONS) Guidelines for Adults (Jun-16)
- Actinic Keratosis (Jun-16)
- Extension of Management of Hypertension Using ABPM guideline for two years (Jul-16)
- Management of Type 2 Diabetes in Adults (Aug-16)
- Management of Pregnant Women and Neonates in Contact with Chickenpox and Shingles (Aug-16)
- Appropriate use and prescribing of infant formula in primary care (Sep-16)
- Heart failure with reduced ejection fraction- updated to include positioning of sacubitril/valsartan (Sep-16)
- Guideline for the Management of Clostridium Difficile Infection in Primary Care – Extension for six months (Sep-16)
- Nicotine replacement therapy – Extension for two months (Sep-16)
- Management of non-valvular atrial fibrillation (Oct-16)
- Management of pregnant women and neonates in contact with measles guidance (Oct-16)
- Management of Lower Urinary Tract Infection (UTI) in Chronic Kidney Disease (CKD) (Oct-16)
- Oxygen (extension to January 2017) (Nov-16)
- Amiodarone monitoring protocol (Dec-16)
- Bowel cleansing (Dec-16)
- Clozapine (Dec-16)
- Use of Compression Hosiery (Dec-16)
- Management of Emergency Contraception with Ulipristal Acetate 30 mg (ellaOne®) (Dec-16)
- Management of hypertension using Ambulatory Blood Pressure Monitoring (ABPM) (Dec-16)
- Topical tacrolimus in primary care (Dec-16)
- Derbyshire Community Dressing Formulary and Wound Care Guidelines 2016 (Dec-16)
- Antipsychotic Physical Health Monitoring (Jan-17)
- Management of Chronic Rhinosinusitis (Jan-17)
- Guidance on prescribing of Low Molecular Weight Heparin (Enoxaparin® and Tinzaparin®) - Guideline agreed and shared care removed. (Feb-17)
- OPAT (Outpatient and Parenteral Antimicrobial Therapy) Policy for Primary Care (Step-Up Pathway) between DCHSFT and CRHFT. (Feb-17)
- Management of Dementia in Primary Care (Mar-17)
- Osteoporosis (Mar-17)
- Phosphate binders guideline for the long-term treatment of hyperphosphataemia in patients on dialysis (Mar-17)
- Vitamin supplementation in alcohol misuse (Mar-17)
- Sayana Press® (Medroxyprogesterone Acetate) primary care protocol (Mar-17)

### **Shared care agreements ratified**

- Methotrexate (oral/subcutaneous/intramuscular preparations for CRHFT/North Derbyshire and oral only preparations for DTHFT/South Derbyshire) (May-16)
- Acamprosate and Disulfiram – Extension to April 2017 (Sep-16)
- Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adults – Extension to November 2016 (Sep-16)
- Memantine and Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease (Sep-16)
- Apomorphine in the Treatment of Parkinson's Disease (Sep-16)
- Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adults (Oct-16)
- Buprenorphine sublingual 0.4mg, 2mg and 8mg tablets in opioid dependency (Oct-16)

- Methadone 1mg/ml oral solution in opioid dependency (Oct-16)
- Naltrexone 50mg tablets for opioid relapse prevention (Oct-16)
- Somatropin (Synthetic Human Growth Syndrome) (Oct-16)
- Lanreotide and octreotide somatostatin analogues (Jan-17)
- Vigabatrin shared care agreement for children with epilepsy (Jan-17)
- Methotrexate between Stepping Hill Hospital and North Derbyshire CCG (Mar-17)
- Denosumab for the prevention of osteoporotic fractures in men and post-menopausal women (Mar-17)

### **Patient Group Directions (PGDs) ratified**

- Measles, Mumps and Rubella (MMR) Vaccine (Apr-16)
- Pneumococcal Polysaccharide Vaccine (PPV) (Apr-16)
- Meningococcal Group C (May-16)
- Haemophilus influenzae type B and meningococcal C conjugate vaccine (Hib/MenC) (Jun-16)
- Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV) (Jun-16)
- Zostavax® reconstituted lyophilised suspension. Shingles (herpes zoster) vaccine, live. (Jun-16)
- Low dose diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) (Jun-16)
- Human papillomavirus vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) (HPV) (Jun-16)
- Live attenuated influenza vaccine (LAIV) nasal spray suspension (Fluenz Tetra®▼) by currently registered nurses, pharmacists or paramedics (Aug-16)
- Administration of intradermal inactivated influenza vaccine (Intanza®) to individuals from 60 years of age in accordance with the national immunisation programme for active immunisation against influenza (Sep-16)
- Administration of intramuscular (or subcutaneous) inactivated influenza vaccine to individuals in accordance with the national immunisation programme for active immunisation against influenza (Sep-16)
- Administration of Haemophilus influenzae type b and meningococcal C conjugate vaccine (Hib/MenC) to individuals from their first birthday to under 10 years of age in accordance with the national immunisation programme for active immunisation against Haemophilus influenzae type b and Neisseria meningitidis capsular group C. (Sep-16)
- Administration of shingles (herpes zoster, live) vaccine to individuals who are eligible for the national shingles immunisation programme for the prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) (Sep-16)
- Pneumococcal Polysaccharide Vaccine (PPV) (Oct-16)
- Administration of Haemophilus influenzae type b and meningococcal C conjugate vaccine (Hib/MenC) to individuals, from their second birthday, with an underlying medical condition. (Dec-16)
- Administration of meningococcal group A, C, W, and Y conjugate vaccine (MenACWY) to individuals with an underlying medical condition which puts them at increased risk from Neisseria meningitidis. (Mar-17)
- Administration of meningococcal group B vaccine (rDNA, component, adsorbed) to individuals, from 2 years of age, with an underlying medical condition which puts them at increased risk from Neisseria meningitidis group B. (Mar-17)
- Administration of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals with an underlying medical condition which puts them at increased risk from pneumococcal disease. (Mar-17)
- Administration of meningococcal group B vaccine (rDNA, component, adsorbed) to individuals from 8 weeks of age eligible for the national routine immunisation programme and to individuals for the prevention of secondary cases of meningococcal group B disease for active immunisation against Neisseria meningitidis group B. (Mar-17)

### **Local PGDs (Derbyshire use only)**

- Levonorgestrel 1500 microgram tablet (Levonelle®) (May-16)
- North Derbyshire MSK service: Methylprednisolone Acetate 40 mg/ml (Nov-16)
- Derbyshire Health United: (Nov-16)
  - Amoxicillin
  - Codeine

- Doxycycline
- Erythromycin
- Ibuprofen suspension
- Ibuprofen tablets
- Nitrofurantoin
- Paracetamol suspension
- Paracetamol tablets
- Phenoxymethylpenicillin tablets
- Chlorphenamine suspension
- Chlorphenamine tablets
- Clarithromycin
- Erythromycin
- Flucloxacillin
- Prednisolone 5mg tablet
- Salbutamol 100mcg inhaler
- Triamcinolone Acetonide for the treatment of joint pain, swelling and stiffness associated with rheumatoid or osteoarthritis, bursitis, tendonopathy and tenosynovitis - Hardwick Federation only (Dec-16)

### **MHRA Drug safety alerts (only primary care related)**

All MHRA drug safety alerts are tabled at JAPC and Guideline Group (and at provider Trusts), but only those relevant to primary care are highlighted.

- SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis (May 2016)
- Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy (May 2016)
- Fingolimod (Gilenya): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections (May 2016)
- Apomorphine with domperidone: minimising risk of cardiac side effects (May 2016)
- Live attenuated vaccines: avoid use in those who are clinically immunosuppressed (May 2016)
- Meprobamate: licence to be cancelled (May 2016)
- Paraffin-based skin emollients on dressings or clothing: fire risk (May 2016)
- BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (Jun 2016)
- QRISK2 (Jun 2016)
- Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations in trial in high cardiovascular risk patients (Jul 2016)
- Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung (Jul 2016)
- Topical miconazole, including oral gel: reminder of potential for serious interaction with warfarin (Jul 2016)
- Warfarin: reports of calciphylaxis (Aug 2016)
- Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use (Aug 2016)
- Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy (Oct 2016)
- Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis (Nov 2016)
- Brimonidine gel (Mirvaso): risk of exacerbation of rosacea (Nov 2016)
- Show your support for reporting suspected adverse drug reactions (Nov 2016)
- Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Jan 17)
- Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification (Jan 17)
- Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation (Feb 17)
- Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR (Feb 17)
- Apremilast (Otezla): risk of suicidal thoughts and behaviour (Feb 17)
- Intravenous N-acetylcysteine (NAC) for paracetamol overdose: reminder of authorised dose regimen; possible need for continued treatment with NAC (Feb 17)

- Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease (Mar 17)

### **Direct healthcare professional communication**

- Canagliflozin-Containing Medicines INVOKANA (canagliflozin), VOKANAMET canagliflozin, metformin) and the risk of Lower Limb Amputation (Primarily of the Toe). (Jun 2016)
- Otezla (apremilast): New important advice regarding suicidal ideation and Behaviour (Jan 2016)

### **Patient safety alert**

- Risk of severe harm and death due to withdrawing insulin from pen devices (Dec 2016)

### **Other decisions**

#### **Biosimilar – Etanercept**

2016 saw the launch of the new etanercept biosimilars – Benepali. Chesterfield Royal Hospital FT began using Benepali in new patients, April 2016 and existing patients began switching June 2016. Royal Derby Hospital commenced discussions regarding use of benepali, April 2016.

#### **Primary care rebates**

Primary care rebates continued to be agreed for use across Derbyshire throughout 2016/17.

#### **Regional Medicines Optimisation Committees (RMOC)**

Regional discussions commenced regarding the creation of four Regional Medicines Optimisation Committees (RMOC) to help eliminate unnecessary duplication of drug appraisals.

#### **QIPP saving opportunities**

- **Bath emollients/shower gels**  
Change in traffic light status to BLACK (not routinely commissioned) across Derbyshire. (Average annual spend across Derbyshire £300,000)
- **Nefopam**  
Classified as BLACK - due to significant cost increase, lack of data clinical effectiveness, lack of data on safety compared with standard treatment and less cost effective than current standard treatment.
- **Alimemazine**  
Classified as BLACK drug – not cost effective and not supported by high quality clinical evidence.
- **Doxazosin MR**  
Classified as BLACK (from Brown), not routinely recommended or commissioned, due to lack of data on clinical and cost effectiveness.
- **All rubefaciants**  
All rubefaciants were classified as BLACK due to lack of evidence of benefit.

#### **Public Health England (PHE) advice Vitamin D**

PHE published advice regarding Vitamin D supplementation for at risk groups. Local guidance was adapted to include the PHE message of 10mcg Vitamin D every day for pregnant and breastfeeding women and people with minimal exposure to sunshine and those from minority ethnic groups.

#### **Medicines prescribed by other healthcare providers.**

JAPC ratified for use the guidance regarding recording of medicines prescribed by other healthcare providers on GP clinical systems. This was advocated on the back of a small audit undertaken at Derby hospital for red drugs prescribed for renal indications.

#### **JAPC working group**

The JAPC working group was established to undertake work across the four CCGs to support work on increasing self-care, prescribing only for clinical need and consideration of difficult decisions. Work undertaken by the group, feeds directly into JAPC. The first meeting was held November 2016 and have continued. A chair and secretary were selected and terms of reference for the group agreed.

**Conflict of interest**

JAPC and Guideline Group established a register for declaration of conflict of interest, to be completed every 6 months.

**High Cost Drug pathways**

Rheumatoid arthritis and ankylosing spondylitis commissioning pathways updated and agreed with new NICE technology appraisals across Derbyshire.

**Low Molecular Weight Heparins**

Enoxaparin and tinzaparin were removed from shared care and reclassified as GREEN specialist initiation. A primary care prescribing guidance for the low molecular weight heparins was produced.

**Management of dementia in primary care**

The shared care agreement for dementia was removed and primary care guidance for the management of dementia was produced in collaboration with the Derbyshire Healthcare FT.

**Communications**

All the JAPC recommendations and publications are available at [www.derbyshiremedicinesmanagement.nhs.uk/home](http://www.derbyshiremedicinesmanagement.nhs.uk/home). This is a public-facing website. A JAPC Bulletin is issued every month, which is a concise outline of that month's JAPC decisions. This is distributed to all GP practices, non-medical prescribers, practice managers, medicine management teams and community pharmacies.

**Summary**

The Derbyshire Joint Area Prescribing Committee continues to make good progress in bringing together clinical decision making and promoting the cost-effective use of medicines across the Derbyshire health economy. It has had excellent primary and secondary care representation, has been well attended, and delivers a significant improvement in governance associated with medicines use for all the participating organisations.

**Recommendation**

The CCG Governing Bodies (or equivalent) of member organisations are requested to receive and acknowledge the details of this annual report.